Until that happens, we can likely expect prescription drug costs to handily outpace the rate of inflation, and for drugmakers like AbbVie, Amgen, Teva, and AstraZeneca to keep raking in the dough. It also recommends Teva Pharmaceutical Industries. Last year, the so-called "Bad Boy of Pharma," Martin Shkreli, attempted to raise the price of an acquired therapeutic known as Daraprim by more roughly 5,500% without changing the formulation or manufacturing process one iota.